Shopping Cart 0
Cart Subtotal
USD 0

cancer testis antigen 1 (autoimmunogenic cancer testis antigen ny eso 1 or cancer testis antigen 6.1 or l antigen family member 2 or ctag1a or ctag1b)-pipeline review, h2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Pipeline Review, H2 2017

Summary

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 6 and 4 respectively. Similarly, the universities portfolio in Phase I stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Metastatic Melanoma, Soft Tissue Sarcoma, Lung Cancer, Metastatic Ovarian Cancer, Synovial Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Melanoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Advanced Malignancy, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Bladder Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Myxoid Liposarcoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Rhabdomyosarcoma, Round Cell Liposarcoma, Sarcomas, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Uterine Cancer.

The latest report CancerTestis Antigen 1-Pipeline Review, H2 2017, outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)

-The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects

-The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Overview 7

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 14

Products under Development by Universities/Institutes 19

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Therapeutics Assessment 21

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Companies Involved in Therapeutics Development 25

Boehringer Ingelheim GmbH 25

Celldex Therapeutics Inc 26

GlaxoSmithKline Plc 27

Immune Design Corp 28

ImmunoFrontier Inc 29

Sanofi Pasteur SA 29

Scancell Holdings Plc 30

Vault Pharma Inc 30

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Drug Profiles 31

BI-1361849-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CDX-1401-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CMB-305-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CMB-305 + G-100-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CUE-102-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

CYN-101-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

G-305-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

GSK-2241658A-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

IMF-001-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

IMM-65-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

LV-305-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

SCIB-2-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

VCP-2292-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

VPI-111-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Dormant Products 56

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Discontinued Products 59

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Product Development Milestones 60

Featured News & Press Releases 60

Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe 60

Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting 60

Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine 62

May 17, 2017: New Clinical and Biomarker Data Validate Immune Design's CMB305 Program 63

Dec 05, 2016: Celldex Presents Data on CDX-1401 at the American Society of Hematology Annual Meeting 64

Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer 64

Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO 65

Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO 66

Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma 66

Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 68

Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016 68

Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305 69

Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 69

Nov 11, 2015: Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients with Soft Tissue Sarcoma 70

Aug 12, 2015: Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration 70

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18

Number of Products under Investigation by Universities/Institutes, H2 2017 19

Products under Investigation by Universities/Institutes, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Pipeline by Boehringer Ingelheim GmbH, H2 2017 25

Pipeline by Celldex Therapeutics Inc, H2 2017 26

Pipeline by GlaxoSmithKline Plc, H2 2017 27

Pipeline by Immune Design Corp, H2 2017 28

Pipeline by ImmunoFrontier Inc, H2 2017 29

Pipeline by Sanofi Pasteur SA, H2 2017 29

Pipeline by Scancell Holdings Plc, H2 2017 30

Pipeline by Vault Pharma Inc, H2 2017 30

Dormant Products, H2 2017 56

Dormant Products, H2 2017 (Contd..1), H2 2017 57

Dormant Products, H2 2017 (Contd..2), H2 2017 58

Discontinued Products, H2 2017 59

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

GlaxoSmithKline Plc

Immune Design Corp

ImmunoFrontier Inc

Sanofi Pasteur SA

Scancell Holdings Plc

Vault Pharma Inc

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Pipeline Review, H2 2017

Summary

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 6 and 4 respectively. Similarly, the universities portfolio in Phase I stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Metastatic Melanoma, Soft Tissue Sarcoma, Lung Cancer, Metastatic Ovarian Cancer, Synovial Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Melanoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Advanced Malignancy, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Bladder Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Myxoid Liposarcoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Rhabdomyosarcoma, Round Cell Liposarcoma, Sarcomas, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Uterine Cancer.

The latest report CancerTestis Antigen 1-Pipeline Review, H2 2017, outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)

-The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects

-The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Overview 7

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 14

Products under Development by Universities/Institutes 19

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Therapeutics Assessment 21

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Companies Involved in Therapeutics Development 25

Boehringer Ingelheim GmbH 25

Celldex Therapeutics Inc 26

GlaxoSmithKline Plc 27

Immune Design Corp 28

ImmunoFrontier Inc 29

Sanofi Pasteur SA 29

Scancell Holdings Plc 30

Vault Pharma Inc 30

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Drug Profiles 31

BI-1361849-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CDX-1401-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CMB-305-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CMB-305 + G-100-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CUE-102-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

CYN-101-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

G-305-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

GSK-2241658A-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

IMF-001-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

IMM-65-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

LV-305-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

SCIB-2-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

VCP-2292-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

VPI-111-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Dormant Products 56

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Discontinued Products 59

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)-Product Development Milestones 60

Featured News & Press Releases 60

Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe 60

Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting 60

Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine 62

May 17, 2017: New Clinical and Biomarker Data Validate Immune Design's CMB305 Program 63

Dec 05, 2016: Celldex Presents Data on CDX-1401 at the American Society of Hematology Annual Meeting 64

Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer 64

Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO 65

Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO 66

Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma 66

Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 68

Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016 68

Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305 69

Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 69

Nov 11, 2015: Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients with Soft Tissue Sarcoma 70

Aug 12, 2015: Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration 70

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18

Number of Products under Investigation by Universities/Institutes, H2 2017 19

Products under Investigation by Universities/Institutes, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Pipeline by Boehringer Ingelheim GmbH, H2 2017 25

Pipeline by Celldex Therapeutics Inc, H2 2017 26

Pipeline by GlaxoSmithKline Plc, H2 2017 27

Pipeline by Immune Design Corp, H2 2017 28

Pipeline by ImmunoFrontier Inc, H2 2017 29

Pipeline by Sanofi Pasteur SA, H2 2017 29

Pipeline by Scancell Holdings Plc, H2 2017 30

Pipeline by Vault Pharma Inc, H2 2017 30

Dormant Products, H2 2017 56

Dormant Products, H2 2017 (Contd..1), H2 2017 57

Dormant Products, H2 2017 (Contd..2), H2 2017 58

Discontinued Products, H2 2017 59

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

GlaxoSmithKline Plc

Immune Design Corp

ImmunoFrontier Inc

Sanofi Pasteur SA

Scancell Holdings Plc

Vault Pharma Inc